Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer

Colorectal Cancer Clinical Trial

— AVAMET  

Official title:

Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01493713
• Other study ID #: GEMCAD-10-06
• Status: Completed
• Phase: Phase 4
• First received: November 22, 2011
• Last updated: February 14, 2018
• Start date: November 16, 2011
• Est. completion date: December 18, 2017

Study information

• Verified date: February 2018
• Source: Grupo Espanol Multidisciplinario del Cancer Digestivo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to to evaluate the correlation of overall objective response according to RECIST v1.1. criteria evaluated by conventional imaging techniques, morphologic response by CT, and histopathologic response in patients with resectable hepatic metastasis secondary to colorectal cancer treated with bevacizumab in combination with XELOX.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: December 18, 2017
• Est. primary completion date: December 8, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent.

2. Age = 18 years.

3. ECOG 0-1.

4. Life expectancy of at least 12 weeks.

5. Histologic confirmation of adenocarcinoma of the colon or rectum, according to the 7th edition of the TNM classification, with evidence of liver metastases according to RECIST v 1.1 criteria (Annex V). Patients with the diagnosis of liver metastasis presenting synchronically or after a disease-free interval. The primary tumor shall have been resected previously although the inverse approach may be acceptable if the tumor is not very symptomatic. Patients in whom combined surgery of the primary tumor and metastases is planned are not eligible.

6. Availability of a tumor sample for KRAS gene determination.

7. No prior chemotherapy treatment for metastatic CRC.

8. Patients with resectable hepatic metastases of colorectal carcinoma who satisfy the following criteria:

• = 4 metastases

• Size < 10 cm

• Technically feasible R0 resection, with a residual liver volume of no less than 30%

NOTE: Patients with bilateral metastases may be enrolled if they satisfy the above criteria (<4 metastases and size <10 cm).

9. Adequate bone marrow, liver and kidney function, defined as:

• Hemoglobin = 9.0 g/dl (a transfusion can be given before treatment).

• Platelet count = 100 × 109/L.

• Absolute neutrophil count (ANC) = 1.5 × 109/L.

• Serum bilirubin = 1.5 times higher than the upper limit of normality (ULN).

• Alkaline phosphatase, ALT (SGPT) and AST (SGOT) = 5 × ULN.

• Serum creatinine < 1.5 x ULN or creatinine clearance = 50 ml/min according to Cockcroft and Gault formula (Annex VII).

• INR < 1.5 within the 7 days prior to the start of study treatment. aPTT < 1.5 × ULN within 7 days prior to the start of study treatment. Exception: Patients treated with complete doses of anticoagulants due to venous thromboembolism usually must have an INR value within the established range (usually 2-3). The patient must be receiving a stable dose of anticoagulant treatment before enrollment in the study.

• Urine strip for proteinuria < 2+. If the result of the reactive strip in urine is = 2+, the 24-hour urine sample must demonstrate = 1 g protein in 24 hours in order to include the patient.

10. Women of childbearing potential must have a negative pregnancy test in serum or urine in the 7-day period before entering the study. Postmenopausal women must have been amenorrheic during at least 12 months. Likewise, both the men and the women who participate in this study must use effective contraceptive methods (e.g., abstinence, intrauterine device, oral contraceptives, a double barrier method or surgical sterility), beginning upon signing the informed consent form and for at least 6 months after the end of treatment or the last dose, whichever occurs first.

11. The subject must have the capacity, in the opinion of the investigator, to comply with all the procedures and examinations of study follow-up.

Exclusion Criteria:

1. Patients with non-resectable hepatic metastases at the time of enrollment.

2. Previous systemic or local treatment of metastatic disease.

3. Presence of metastatic extrahepatic disease.

4. Neo-adjuvant or adjuvant chemotherapy/radiotherapy in the 6 months prior to entering the study.

5. Use of any investigational drug in the 4 weeks before starting the study treatment.

6. Current or recent (in the 10 days prior to the first administration of the study treatment) use of acetylsalicylic acid (> 325 mg/day) or clopidogrel (75 mg/day).

7. Current presence of peripheral neuropathy = 1 (CTCAE).

8. Hypertension not properly controlled (defined as systolic pressure > 150 mm Hg and/or diastolic pressure > 100 mm Hg in repeated measurements), despite optimal medical management.

9. Previous history of hypertensive episodes or hypertensive encephalopathy.

10. CHF class II or higher of the NYHA classification.

11. History of myocardial infarction or unstable angina within the 6 months prior to starting the study treatment.

12. Significant vascular disease (e.g., aortic aneurysm requiring surgery, pulmonary embolism or recent peripheral arterial thrombosis) in the 6 months prior to the start of the study treatment.

13. History of hemoptysis (equivalent to = ½ teaspoon of red-colored blood per episode) in the month prior to the study treatment.

14. Major surgery, open surgical biopsy or significant trauma in the 4 weeks prior to the start of study treatment. Thick-needle biopsy of a major organ in the 7 days prior to entering the study. Insertion of a vascular access > 3 days before entering the study is allowed.

15. Tests or history of significant hemorrhagic diathesis or coagulation disorder (in the absence of anticoagulation).

16. History of abdominal fistula or gastrointestinal perforation in the 6 months prior to the start of study treatment.

17. Intra-abdominal acute inflammatory process.

18. Serious unhealed wounds, active ulcer or untreated bone fracture.

19. History of another neoplastic disease aside from colorectal cancer in the last 2 years prior to the start of study treatment, with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix treated curatively.

20. Human immunodeficiency virus infection or chronic infection by the hepatitis B or C virus or presence of uncontrolled intercurrent infections, or other severe uncontrolled concomitant diseases.

21. Current grade = 2 infection (CTCAE).

22. Pregnant or breast-feeding women.

23. Known allergy, suspicion of allergy, or hypersensitivity to any of the study drugs (bevacizumab, oxaliplatin, capecitabine) and/or iodide contrast agents.

24. Incapacity for oral intake.

25. Any important and uncontrolled medical, psychological, psychiatric or social problem that can interfere in the subject's participation in the study or the evaluation of the study results or represents and increased risk of complications related to the patient's treatment.

26. Patients in whom combined surgery of the primary tumor and metastases is planned are not eligible.

27. Venous Cava invasion and 2 or more hepatic venous invasion Both portal venous invasion Remanent future minor to 40% Use of portal embolization previous to hepatectomy.

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Hepatic Metastasis
• Liver Neoplasms
• Neoplasm Metastasis

Intervention

Other:
• Evaluate the correlation of overall different objective response.
Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)

Locations

Country	Name	City	State
Spain	Hospital Universitario Fundación Alcorcón	Alcorcón	Madrid
Spain	Hospital Clìnic	Barcelona
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital Universitario Virgen de la Arrixaca	El Palmar	Murcia
Spain	Hospital Universitario Arnau de Vilanova de Lleida	Lérida
Spain	Complejo Hospitalario Xeral Calde	Lugo
Spain	Hospital General Universitario Gregorio Marañón	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Puerta de Hierro de Majadahonda	Majadahonda	Madrid
Spain	Complejo Hospitalario Universitario de Ourense	Orense
Spain	Hospital Universitario Central de Asturias	Oviedo
Spain	Hospital Son Llatzer	Palma de Mallorca	Mallorca
Spain	Hospital de Navarra	Pamplona	Navarra
Spain	Hospital de Sabadell	Sabadell
Spain	Hospital de Donostia	San Sebastián	Guipúzcoa
Spain	Hospital Arnau de Vilanova de Valencia	Valencia
Spain	Hospital General Universitario de Valencia	Valencia
Spain	Hospital Universitario y Politécnico La Fe	Valencia
Spain	Complejo Hospitalario Universitario de Vigo	Vigo
Spain	Hospital Universitario Miguel Servet	Zaragoza

Sponsors (1)

Lead Sponsor	Collaborator
Grupo Espanol Multidisciplinario del Cancer Digestivo

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of overall objective responses evaluated by conventional imaging techniques with the morphologic response evaluated by MDCT and the histopathologic response after the resection of hepatic metastases.		2016
Secondary	R0/R1/R2 resectability rate.		2016
Secondary	Progression-free survival (PFS), only in patients who do not undergo metastasis resection.		2016
Secondary	Recurrence-free survival (RFS) in patients who undergo metastasis resection.		2016
Secondary	Safety and toxicity (surgical and therapeutic) of the therapy graded according to CTC v.4.0		2016
Secondary	Overall survival (OS) at 2 and 3 years.		2016
Secondary	Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on overall objective response		2016
Secondary	Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on surgical resection rate		2016
Secondary	Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on survival		2016
Secondary	Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on progression free survival		2016